C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells

Experimental Neurology

Volumn 277, Issue , 2016, Pages 171-177

  Esanov, Rustam ^a   Belle, Kinsley C ^a   van Blitterswijk, Marka ^b   Belzil, Veronique V ^b   Rademakers, Rosa ^b   Dickson, Dennis W ^b   Petrucelli, Leonard ^b   Boylan, Kevin B ^c   Dykxhoorn, Derek M ^a   Wuu, Joanne ^a   Benatar, Michael ^a   Wahlestedt, Claes ^a   Zeier, Zane ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Amyotrophic lateral sclerosis; C9orf72; Cytosine hydroxymethylation; Repeat expansion

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; C9ORF72 PROTEIN, HUMAN; CYTOSINE; GREEN FLUORESCENT PROTEIN; HOMEODOMAIN PROTEIN; MESSENGER RNA; NANOG PROTEIN, HUMAN; NESTIN; PROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; C9ORF72 GENE; CELL ASSAY; CELL FATE; CELL REPROGRAMMING TECHNIQUE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYMETHYLATION; HYPERMETHYLATION; METHYLATION; MOTONEURON; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; ANALOGS AND DERIVATIVES; BRAIN; COCULTURE; CPG ISLAND; GENETICS; INDUCED PLURIPOTENT STEM CELL; LYMPHOCYTE; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; TIME FACTOR;

5-METHYLCYTOSINE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; COCULTURE TECHNIQUES; CPG ISLANDS; CYTOSINE; DNA METHYLATION; GREEN FLUORESCENT PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LYMPHOCYTES; MOTOR NEURONS; MUTATION; NANOG HOMEOBOX PROTEIN; NESTIN; PROMOTER REGIONS, GENETIC; PROTEINS; RNA, MESSENGER; SOXB1 TRANSCRIPTION FACTORS; TIME FACTORS;

EID: 84953889368     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.12.022     Document Type: Article

References (52)

1. Al-Mahdawi S., Sandi C., Mouro Pinto R., Pook M.A. Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus. PLoS One 2013, 8(9):e74956.
2. Almeida S., Gascon E., Tran H., et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013, 126(3):385-399. (Sep).
3. Amoli M.M., Carthy D., Platt H., Ollier W.E. EBV immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int. J. Epidemiol. 2008, 37(Suppl. 1):i41-i45. (Apr).
4. Ash P.E., Bieniek K.F., Gendron T.F., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77(4):639-646. (Feb 20).
5. Belzil V.V., Bauer P.O., Gendron T.F., Murray M.E., Dickson D., Petrucelli L. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res. 2014, 1584:15-21. (Oct 10).
6. Castaldo I., Pinelli M., Monticelli A., et al. DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J. Med. Genet. 2008, 45(12):808-812. (Dec).
7. Chen J., Guo L., Zhang L., et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat. Genet. 2013, 45(12):1504-1509. (Dec).
8. Cheng Y., Xie N., Jin P., Wang T. DNA methylation and hydroxymethylation in stem cells. Cell Biochem. Funct. 2015, 33(4):161-173. (Jun).
9. Choi S.M., Liu H., Chaudhari P., et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 2011, 118(7):1801-1805. (Aug 18).
10. Costa Y., Ding J., Theunissen T.W., et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013, 495(7441):370-374. (Mar 21).
11. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72(2):245-256. (Oct 20).
12. Ficz G., Branco M.R., Seisenberger S., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473(7347):398-402. (May 19).
13. Freibaum B.D., Lu Y., Lopez-Gonzalez R., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 2015, 525(7567):129-133. (Sep 3).
14. Gendron T.F., Belzil V.V., Zhang Y.J., Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 2014, 127(3):359-376. (Mar).
15. Gijselinck I., Van Mossevelde S., van der Zee J., et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol. Psychiatry 2015, (Oct 20) http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2015159a.html.
16. Globisch D., Munzel M., Muller M., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 2010, 5(12):e15367.
17. Hill P.W., Amouroux R., Hajkova P. DNA demethylation, Tet proteins and 5-hydroxymethylcytosine in epigenetic reprogramming: an emerging complex story. Genomics 2014, 104(5):324-333. (Nov).
18. Huang Y., Pastor W.A., Shen Y., Tahiliani M., Liu D.R., Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2010, 5(1):e8888.
19. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466(7310):1129-1133. (Aug 26).
20. Jin S.G., Wu X., Li A.X., Pfeifer G.P. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 2011, 39(12):5015-5024. (Jul).
21. Jovicic A., Mertens J., Boeynaems S., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015, 18(9):1226-1229. (Sep).
22. Kaas G.A., Zhong C., Eason D.E., et al. TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron 2013, 79(6):1086-1093. (Sep 18).
23. Kinney S.M., Chin H.G., Vaisvila R., et al. Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes. J. Biol. Chem. 2011, 286(28):24685-24693. (Jul 15).
24. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324(5929):929-930. (May 15).
25. Leitch H.G., McEwen K.R., Turp A., et al. Naive pluripotency is associated with global DNA hypomethylation. Nat. Struct. Mol. Biol. 2013, 20(3):311-316. (Mar).
26. Liu E.Y., Russ J., Wu K., et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol. 2014, 128(4):525-541. (Oct).
27. McLennan Y., Polussa J., Tassone F., Hagerman R. Fragile x syndrome. Curr. Genomics 2011, 12(3):216-224. (May).
28. McMillan C.T., Russ J., Wood E.M., et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology 2015, 84(16):1622-1630. (Apr 21).
29. Rajesh D., Dickerson S.J., Yu J., Brown M.E., Thomson J.A., Seay N.J. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood 2011, 118(7):1797-1800. (Aug 18).
30. Renton A.E., Majounie E., Waite A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72(2):257-268. (Oct 20).
31. Santiago M., Antunes C., Guedes M., Sousa N., Marques C.J. TET enzymes and DNA hydroxymethylation in neural development and function - how critical are they?. Genomics 2014, 104(5):334-340. (Nov).
32. Sherwani S.I., Khan H.A. Role of 5-hydroxymethylcytosine in neurodegeneration. Gene 2015, 570(1):17-24. (Oct 1).
33. Son E.Y., Ichida J.K., Wainger B.J., et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011, 9(3):205-218. (Sep 2).
34. Stroud H., Feng S., Morey Kinney S., Pradhan S., Jacobsen S.E. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol. 2011, 12(6):R54.
35. Szulwach K.E., Li X., Li Y., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 2011, 14(12):1607-1616. (Dec).
36. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935. (May 15).
37. Tosato G., Cohen J.I. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr. Protoc. Immunol. 2007, (Feb, Chapter 7:Unit 7 22).
38. van Blitterswijk M., Rademakers R. Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport. Nat. Rev. Neurol. 2015, (Nov 3).
39. van Blitterswijk M., DeJesus-Hernandez M., Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. Curr. Opin. Neurol. 2012, 25(6):689-700. (Dec).
40. van Blitterswijk M., DeJesus-Hernandez M., Niemantsverdriet E., et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013, 12(10):978-988. (Oct).
41. Wang T., Pan Q., Lin L., et al. Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. Hum. Mol. Genet. 2012, 21(26):5500-5510. (Dec 15).
42. Wang F., Yang Y., Lin X., et al. Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease. Hum. Mol. Genet. 2013, 22(18):3641-3653. (Sep 15).
43. Wu H., D'Alessio A.C., Ito S., et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 2011, 25(7):679-684. (Apr 1).
44. Xi Z., Zinman L., Moreno D., et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 2013, 92(6):981-989. (Jun 6).
45. Xi Z., Rainero I., Rubino E., et al. Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum. Mol. Genet. 2014, 23(21):5630-5637. (Nov 1).
46. Yanovsky-Dagan S., Mor-Shaked H., Eiges R. Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells. World J. Stem Cells 2015, 7(5):823-838. (Jun 26).
47. Yao B., Lin L., Street R.C., et al. Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome. Hum. Mol. Genet. 2014, 23(4):1095-1107. (Feb 15).
48. Zeier Z., Esanov R., Belle K.C., et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Exp. Neurol. 2015, (Jun 19).
49. Zhang D., Iyer L.M., He F., Aravind L. Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front. Genet. 2012, 3:283.
50. Zhang K., Donnelly C.J., Haeusler A.R., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 2015, 525(7567):56-61. (Sep 3).
51. Zu T., Gibbens B., Doty N.S., et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(1):260-265. (Jan 4).
52. Zu T., Liu Y., Banez-Coronel M., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(51):E4968-E4977. (Dec 17).